Premium
Review article: the endocannabinoid system in liver disease, a potential therapeutic target
Author(s) -
Basu P. P.,
Aloysius M. M.,
Shah N. J.,
Brown Jr R. S.
Publication year - 2014
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/apt.12673
Subject(s) - endocannabinoid system , medicine , liver disease , cannabinoid receptor , disease , fatty liver , chronic liver disease , adverse effect , pharmacology , receptor , cirrhosis , agonist
Summary Background Endocannabinoids are a family of potent lipid‐soluble molecules, acting on the cannabinoid (CB) receptors that mediate the effects of marijuana. The CB receptors, endocannabinoids and the enzymes involved in their synthesis and degradation are located in the brain and peripheral tissues, including the liver. Aims To review the current understanding of the role of the endocannabinoid system in liver disease‐associated pathophysiological conditions, and drugs targeting the endocannabinoid system as therapy for liver disease. Methods Original articles and reviews were used to summarise the relevant pre‐clinical and clinical research findings relating to this topic. Results The endocannabinoid system as a whole plays an important role in liver diseases (i.e. non‐alcoholic liver disease, alcoholic liver disease, hepatic encephalopathy and autoimmune hepatitis) and related pathophysiological conditions (i.e. altered hepatic haemodynamics, cirrhotic cardiomyopathy, metabolic syndrome and ischaemia/reperfusion disease). Pharmacological targeting of the endocannabinoid system has had success as treatment for patients with liver disease, but adverse events led to withdrawal of marketing approval. However, there is optimism over novel therapeutics targeting the endocannabinoid system currently in the pre‐clinical stage of development. Conclusions The endocannabinoid system plays an important role in the pathophysiology of liver disease and its associated conditions. While some drugs targeting the endocannabinoid system have deleterious neurological adverse events, there is promise for a newer generation of therapies that do not cross the blood–brain barrier.